Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKRGet Free Report) was the target of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 64,400 shares, a decrease of 40.3% from the March 31st total of 107,900 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 18,700 shares, the days-to-cover ratio is currently 3.4 days.

Marker Therapeutics Price Performance

Shares of NASDAQ MRKR opened at $4.37 on Friday. The stock has a 50-day moving average price of $4.27 and a two-hundred day moving average price of $3.96. Marker Therapeutics has a 12 month low of $0.76 and a 12 month high of $9.68.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Marker Therapeutics stock. International Assets Investment Management LLC lifted its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKRFree Report) by 1,000.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. International Assets Investment Management LLC owned about 0.12% of Marker Therapeutics worth $60,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.

Featured Articles

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with's FREE daily email newsletter.